Michael A. Rogawski MD, PhD

Dr. Rogawski is professor and chair of the Department of Neurology at the University of California, Davis. Until 2006, he was a senior investigator and chief of the Epilepsy Research Section at the National Institute of Neurological Disorders and Stroke. Dr. Rogawski received his BA from Amherst College and MD and Ph.D. (pharmacology) from Yale University. After serving as a postdoctoral fellow in the Laboratory of Neurophysiology, NINDS, he completed residency training in neurology at Johns Hopkins.

Dr. Rogawsk's research encompasses cellular neurophysiological studies of ion channels (with a focus on the mechanisms of action of antiepileptic drugs); animal models of epilepsy, migraine, and nerve agent intoxication; and clinical studies on new treatments for seizures, epilepsy, migraine, traumatic brain injury, and neurodevelopmental disorders. His laboratory studies on AMPA receptors and neurosteroids have led to new epilepsy treatment approaches.

Dr. Rogawski has received the NIH Director's Award and the Epilepsy Research Award for Outstanding Contributions to the Pharmacology of Antiepileptic Drugs from the American Society for Pharmacology and Experimental Therapeutics. He presented the British Pharmacological Society Lecture, the Killam Lecture of the Montreal Neurological Institute, and the American Epilepsy Society's William G. Lennox Lecture.

Dr. Rogawski has served on the editorial boards of Molecular Pharmacology, Epilepsia, Epilepsy Research, Synapse, CNS Drug Reviews, Current Neuropharmacology, Pharmacology & Therapeutics, BMC Pharmacology, Cellular, and Molecular Neurobiology, and Nature Scientific Reports. He is the founder and a chief editor of Epilepsy Currents, the journal of the American Epilepsy Society, and he is associate editor of Neurotherapeutics, the journal of the American Society for Experimental NeuroTherapeutics. He has served on the board of directors of the American Epilepsy Society, has been a member of advisory panels to the National Institutes of Health, and serves in an advisory capacity as a special government employee to the Food and Drug Administration. He is a board member and president-elect of the American Society for Experimental NeuroTherapeutics.